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Abstract
Introduction: Positron Emission Tomography - Computer Tomography (PET-CT) is an interesting imaging
technique to visualize Ankylosing Spondylitis (AS) activity using specific PET tracers. Previous studies have shown
that the PET tracers [18F]FDG and [11C](R)PK11195 can target inflammation (synovitis) in rheumatoid arthritis (RA)
and may therefore be useful in AS. Another interesting tracer for AS is [18F]Fluoride, which targets bone formation.
In a pilot setting, the potential of PET-CT in imaging AS activity was tested using different tracers, with Magnetic
Resonance Imaging (MRI) and conventional radiographs as reference.
Methods: In a stepwise approach different PET tracers were investigated. First, whole body [18F]FDG and [11C](R)
PK11195 PET-CT scans were obtained of ten AS patients fulfilling the modified New York criteria. According to
the BASDAI five of these patients had low and five had high disease activity. Secondly, an extra PET-CT scan
using [18F]Fluoride was made of two additional AS patients with high disease activity. MRI scans of the total
spine and sacroiliac joints were performed, and conventional radiographs of the total spine and sacroiliac joints
were available for all patients. Scans and radiographs were visually scored by two observers blinded for clinical
data.
Results: No increased [18F]FDG and [11C](R)PK11195 uptake was noticed on PET-CT scans of the first 10 patients.
In contrast, MRI demonstrated a total of five bone edema lesions in three out of 10 patients. In the two
additional AS patients scanned with [18F]Fluoride PET-CT, [18F]Fluoride depicted 17 regions with increased
uptake in both vertebral column and sacroiliac joints. In contrast, [18F]FDG depicted only three lesions, with an
uptake of five times lower compared to [18F]Fluoride, and again no [11C](R)PK11195 positive lesions were found.
In these two patients, MRI detected nine lesions and six out of nine matched with the anatomical position of
[18F]Fluoride uptake. Conventional radiographs showed structural bony changes in 11 out of 17 [18F]Fluoride PET
positive lesions.
Conclusions: Our PET-CT data suggest that AS activity is reflected by bone activity (formation) rather than
inflammation. The results also show the potential value of PET-CT for imaging AS activity using the bone tracer
[18F]Fluoride. In contrast to active RA, inflammation tracers [18F]FDG and [11C](R)PK11195 appeared to be less useful
for AS imaging.
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Introduction
Ankylosing spondylitis (AS) is a chronic, inflammatory,
rheumatic disease that usually starts at an early age and
can result in irreversible bone deformation and disability
in the long term. AS is characterized by inflammatory
back pain, limited motion of the spine, and sacroiliitis
on plain radiography. Peripheral arthritis and enthesitis
may also be prominent features [1]. Patients with AS are
often treated with non-steroidal anti-inflammatory drugs
(NSAIDs) because they stabilize disease activity over
time and, in addition, can reduce radiographic progres-
sion [2]. However, with the introduction of anti-tumor
necrosis factor (anti-TNF) therapy, a more effective
treatment of AS became possible. Patients with AS seem
to benefit most if treatment with TNF blockers is
started early in the disease course, particularly when
started at a younger age [3,4]. Therefore, it is important
to diagnose this disease early. Until recently, plain radio-
graphs were obligatory for the diagnosis of AS, accord-
ing to the modified New York criteria [5]. The
disadvantage of this imaging technique is that it usually
takes many years before the disease comes to full
expression and definite radiographic sacroiliitis appears
[5]. Consequently, the diagnosis is often delayed by 5 to
10 years, especially in patients with an early or incom-
plete clinical picture [1,6,7]. To enable earlier diagnosis,
highly reliable and sensitive imaging techniques are
needed.
Nowadays, magnetic resonance imaging (MRI) is
believed to be a sensitive imaging modality for the
detection of sacroiliitis and inflammation of the spine in
early AS. MRI detects (early) inflammation by visualiza-
tion of tissue edema or enhanced gadolinium contrast
uptake or both. However, these imaging findings are
non-specific indicators of increased free water content
and increased vascularization, respectively [8,9]. More-
over, chronic AS changes, such as new bone formation
in the spine (syndesmophyte formation), tend to be less
well visualized on MRI than on radiographs [10]. Finally,
although validated scoring methods are available, con-
flicting data on the sensitivity and specificity of MRI in
(suspected) spondylarthropathies have been published
[6,11-14]. Therefore, the precise role of MRI in visualiz-
ing disease activity of AS has not yet been fully
elucidated.
Positron emission tomography (PET) is another inter-
esting imaging technique for the diagnosis of AS. PET
allows sensitive imaging of functional tissue changes
(pathophysiology) in the whole body by targeting bind-
ing sites [15]. The visualization of pathophysiology
makes PET potentially suitable for early detection of
inflammatory processes, even before anatomical changes
occur. Thereby, PET allows specificity through the use
of receptor targeting tracers and allows quantification of
disease activity in order to accurately monitor therapeu-
tic effects [16]. Recently, PET-computed tomography
(PET-CT) scanning was introduced as a hybrid imaging
technique that combines the unique properties of sensi-
tive imaging of pathophysiology and anatomical CT
imaging as a reference [17]. In this way, PET-CT offers
the opportunity to visualize (early) inflammatory
changes as well as (early) structural changes such as
new bone formation, which is hard to detect on MRI.
The definite pathogenesis of AS is still not clear, and
different joint structures may be involved in inflamma-
tory sites in AS [18]. Therefore, different targets for the
PET tracers have to be taken into account. Synovial tis-
sue, bone marrow, entheses, and ligaments can be
affected in AS [19-21] and may need different specific
tissue PET tracers. PET studies in patients with rheuma-
toid arthritis (RA) clearly revealed inflamed synovial tis-
sue through the use of the glucose analogue [18F]-
fluoro-2-deoxy-D-glucose ([18F]FDG), visualizing
increased metabolism in synovial tissue [16,22,23], and
the macrophage tracer PK11195 [(R)-1-(2-chlorophe-
nyl)-N-methyl-N(1-methyl-propyl)-3-isoquinoline car-
boxamide] ([11C](R)PK11195) [24]. [11C](R)PK11195
binds with high affinity to peripheral benzodiazepine
receptors, which are expressed mainly on macrophages
[25]. Since macrophage-rich inflammation has been
demonstrated in patients with AS [26], both [18F]FDG
and [11C](R)PK11195 may be interesting tracers for
detection of disease activity of AS. In addition to inflam-
mation tracers, the bone tracer [18F]fluoride may have
potential for AS imaging since AS is characterized by
syndesmophyte formation and ankylosis in vertebral col-
umn and sacroiliac (SI) joints. [18F]Fluoride uptake in
active bone reflects local blood flow and regional osteo-
blastic activity [27,28]. Indeed, [18F]fluoride appeared to
be a potential tracer for imaging of active bone sites in
a small group of patients with AS [29].
The objective of this pilot study was to investigate the
potential of PET-CT for imaging AS activity by the
investigation of three different tracers in a stepwise
approach with MRI and conventional radiographs as
references for PET-CT data. Inflammation tracers [18F]
FDG and [11C](R)PK11195 were studied in patients with
AS with low and high disease activity, and these inflam-
mation tracers were compared with the bone tracer
[18F]fluoride in additional patients with high disease
activity.
Materials and methods
Patients
Twelve patients who had AS (at least 18 to not more
than 70 years) and who fulfilled the modified New York
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criteria [5] were included between March 2008 and
December 2010. Patients were excluded if they were
pregnant or breast-feeding, had a pacemaker, had a
creatinine clearance of less than 30 mL/minute, or had
any other treatment with investigational drugs within
the previous 3 months. Additionally, benzodiazepines
were discontinued at least 10 days prior to inclusion to
prevent (partial) blockade of benzodiazepine receptors,
relevant for [11C](R)PK11195 binding. NSAIDs were
continued if used at inclusion.
Five patients had low disease activity - Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI) of less
than 4 - and seven patients high disease activity (BAS-
DAI of at least 4). Patients with high disease activity
were candidates for treatment with a TNF-blocking
agent and were included before anti-TNF treatment was
started. The study protocol was approved by the medical
ethics committee. All patients gave written informed
consent prior to participation in the study.
Study design
In a stepwise investigation of different PET tracers, we
studied the potential of PET-CT in AS by using the
inflammation tracers [18F]FDG and [11C](R)PK11195 in
patients with AS with low (n = 5) or high (n = 5) dis-
ease activity and subsequently compared [18F]FDG and
[11C](R)PK11195 with the bone tracer [18F]fluoride in
two patients with high disease activity (n = 2). As refer-
ences for PET-CT data, MRI scans of the total spine
and SI joints were obtained within a mean of 5 days
(range of 0 of 17 days) after the PET-CT scan. Conven-
tional radiographs of the total spine (anterior-posterior
and lateral) and SI joints (posterior-anterior) were avail-
able for all patients.
[18F]-FDG, [11C](R)PK11195, and [18F]fluoride PET-CT scan
Whole-body PET-CT scans were performed by using a
PET-CT type Gemini TF (Philips, Cleveland, OH, USA).
Patients fasted for at least 6 hours prior to scanning
with [18F]FDG. Patients were injected with a mean ±
standard deviation (SD) of 111 ± 6 MBq [18F]FDG and
375 ± 30 MBq [11C](R)PK11195, each injection follwed
by scanning, with a minimal interval period of 3 hours
between the scans. Patients were in a supine position
and entered the scanning machine feet first. All PET
scans were preceded by a low-dose 35-milliampere-sec-
ond CT scan covering the vertebral column and the SI
joints. Low-dose CT was used for attenuation correction
and localization of PET signal and did not allow definite
identification of structural bony lesions. Sixty minutes
after intravenous injection of [18F]FDG and 10 minutes
after intravenous injection of [11C](R)PK11195, whole-
body scans of 5 minutes per field of view (FOV) for
[18F]FDG and 3 to 5 minutes per FOV for [11C](R)
PK11195 were acquired of the total spine and SI joints.
The maximum total scan time was approximately 60 to
75 minutes per patient. The total spine and SI joints
were depicted in one image. Since the tracer [11C](R)
PK11195 may easily stick to application material, the
application system was flushed with 20 mL of NaCl
0.9%, and rest activity was measured after administration
of the tracer.
In two additional patients with high disease activity,
an extra whole-body (5 minutes per FOV) [18F]fluoride
PET-CT was performed 1 hour after injection of (mean
± SD) 108 ± 1 MBq [18F]fluoride. This PET scan was
also preceded by a low-dose 35-milliampere-second CT
scan. The application system was flushed with 20 mL of
NaCl 0.9%, and rest activity was measured after admin-
istration of the tracer.
PET data were normalized and corrected for attenua-
tion, decay, and scatter. All scans were reconstructed as
144 × 144 matrices with a pixel size of 4 × 4 × 4 mm
by using a fully three-dimensional line of response itera-
tive reconstruction, including time-of-flight information
(’Blob-OS-TF’). These reconstructed images were also
used for region-of-interest definition.
MRI scan
A gadolinium-enhanced MRI series of the vertebral col-
umn and SI joints was performed, preferably within 1
week before or after the PET-CT scans, by using a Sie-
mens Magneton Sonata 1.5 Tesla (Siemens Medical
Solutions, Erlangen, Germany). Imaging was done, using
the head/neck and spine array, in coronal and sagittal
orientation with T1-weighted images before and after
gadolinium-contrast plus a short-tau inversion recovery
(STIR) sequence. The technical details are as follows:
matrix 512 × 512 pixels, FOV of 380 mm in sagittal
orientation with slice thicknesses of 3 mm for the cervi-
cal/thoracic region and 4 mm for the thoracic/lumbar
region (voxel sizes of 0.7 × 0.7 × 3.0 mm and 0.7 × 0.7
× 4.0 mm, respectively). The SI region had a 256 matrix
with an FOV of 270 mm in coronal/oblique orientation
and a slice thickness of 4 mm (voxel size of 1.1 × 1.1 ×
4.0 mm). The T1 post-gadolinium series were made
with 0.5 mmol/mL Dotarem(®) (Guerbet, France) 0.2
mL/kg, and the total scan time was approximately 60
minutes.
Imaging analysis
On conventional radiographs, cervical spine and lumbar
spine were visually interpreted and scored according to
the m-SASSS scoring method (score of 0 to 72). Addi-
tionally, the thoracic spine was scored according to the
m-SASSS criteria, although they are not validated for
this part of the spine. However, no other scoring meth-
ods are available for the thoracic spine. In addition, the
involvement of the posterior lesions of the spine was
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visually determined by one observer and a radiologist.
The SI joints were scored according to the modified
New York criteria (score of 0 to 8).
A nuclear medicine specialist and a rheumatologist
qualitatively interpreted PET-CT data. For relative com-
parison of tracer uptake, regions of interests were drawn
in AMIDE (a Medical Imaging Data Examiner) data ana-
lysis software [30]. With the covering low-dose CT as an
anatomical reference, elliptic cylinders and rectangular
boxes were drawn on top of focal hotspots and a (non-
hotspot) vertebral body (in principle, L1, if unaffected)
(background), respectively, to calculate mean uptake
ratios. MRI data were qualitatively evaluated by a radiol-
ogist for subchondral bone marrow edema, gadolinium
enhancement, cartilage abnormalities, periarticular ero-
sions, subchondral fatty marrow infiltration, and
ankylosis.
Statistical analysis
Data and images of this pilot study were analyzed in a
descriptive manner. Owing to the small study popula-
tion, a normal distribution of data is not expected.
Therefore, patient characteristics were analyzed by using
SPSS version 15 (SPSS Inc., Chicago, IL, USA), and
values were presented as median (range).
Results
Patient characteristics
Baseline characteristics of the included patients are sum-
marized in Table 1.
Imaging analysis
[18F]FDG and [11C](R)PK11195 PET-CT with MRI as a
reference
In none of the first 10 patients was focal [18F]FDG or
[11C](R)PK11195 uptake or both noticed (for example,
Figure 1c, d). MRI (STIR) images, on the other hand,
revealed bone edema (n = 5 lesions) in the spine or SI
joints of three out of 10 patients (one with low and two
with high disease activity) (for example, Figures 1e and
2e). Four out of five lesions on STIR also showed gadoli-
nium enhancement on T1 images. Furthermore, in three
patients without bone edema in the SI joints, MRI
revealed local ankylosis or subchondral fatty marrow
infiltration or both (Figure 2j). Of note, background
[11C](R)PK11195 uptake in bone (marrow) was about
five times higher than that of [18F]FDG.
Comparison of [18F]FDG and [11C](R)PK11195 and [18F]
fluoride PET-CT with MRI as a reference
In the two additional patients scanned with [18F]fluor-
ide, [18F]FDG depicted three hotspots in the vertebral
column and [11C](R)PK11195 scans showed no focal
uptake. [18F]Fluoride scans demonstrated 17 regions
with elevated [18F]fluoride tracer uptake in both spine
and SI joints (Table 2). The three regions revealed by
[18F]FDG were also depicted with [18F]fluoride PET-CT
(Figure 2 and Table 2), with an uptake that was five
times higher than the [18F]FDG uptake.
MRI depicted nine bone marrow lesions, with
enhanced signal on both STIR and gadolinium contrast
T1 images, in the spine of these two patients (Table 2).
Only one out of three [18F]FDG hotspots matched with
MRI lesions, and two thirds of the MRI lesions matched
with the anatomical position of [18F]fluoride uptake.
The number of [18F]fluoride lesions (n = 17) exceeded
those detected on MRI (n = 9) (Table 2). Eleven active
lesions were depicted with [18F]fluoride PET-CT and
not on MRI. Three lesions (two cervical and one lumbar
vertebrae) were detected on MRI and not on [18F]fluor-
ide PET. Of note, whole-body [18F]fluoride scans addi-
tionally showed hotspots in the manubriosternal joints
in both patients and in the left acromion-clavicular joint
Table 1 Baseline demographic, clinical, functional, and x-ray characteristics of patients
Low disease activity (BASDAI < 4) (n = 5) High disease activity (BASDAI ≥ 4) (n = 7)
Males/females 4/1 3/4
HLA-B27-positive, percentage 100 57
Age, years 31.0 (25-50) 41.0 (24-56)
Duration since diagnosisa, years 2.0 (0-4) 3.0 (0-20)
Duration of symptomsb, years 12.0 (7-19) 12.0 (1-32)
BASDAI (0-10) 1.7 (0.7-2.2) 6.9 (5.1-9.8)
ESR, mm/hour 14.0 (4-19) 23.0 (2-30)
Sacroiliitis (0-8) 5.0 (4-6) 5.0 (4-7)
m-SASSS (0-72) 2.5 (0-6) 1.6 (0-14)
BASRI-hip (0-8) 1.2 (0-2) 0.75 (0-2)
Values are presented as median (range). aDuration since diagnosis (in years), from definite ankylosing spondylitis (AS) diagnosis according to the modified New
York criteria. bDuration of symptoms (in years), from the start of inflammatory back pain. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASRI-hip,
Bath Ankylosing Spondylitis Index for the Hip (0 to 4, sum of right and left scores); ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte antigen-B27;
m-SASSS, modified Stoke Ankylosing Spondylitis Spinal Score; Sacroiliitis, sacroiliitis scoring according to the radiographic modified New York criteria (0 to 4, sum
of right and left scores).
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in one patient corresponding to clinical symptoms (data
not shown in Table 2).
Comparison of [18F]fluoride PET and MRI with conventional
x-rays
Active sites on [18F]fluoride PET-CT or MRI or both
were compared with structural changes observed on
conventional x-rays (Table 2). In four out of six PET-
and MRI-positive lesions, conventional radiography
depicted sclerosis. In seven out of 11 PET-positive/MRI-
negative lesions, structural changes were found: sclerosis
(n = 1), squaring (n = 3), facet arthrosis (n = 2), and
ankylosis (n = 1). Furthermore, PET or MRI or both
depicted nine active sites with no radiographic structural
changes. Conversely, seven sites with structural changes
on conventional radiography did not depict any activity
on either PET or MRI: sclerosis (n = 3), squaring (n =
2), facet arthrosis (n = 2).
Discussion
Results of this pilot study show the potential of PET-CT
imaging of AS activity. Targeting of bone formation
appears to be the most promising approach to visualize
AS activity. Inflammation tracers ([18F]FDG and [11C](R)
PK11195) seem to be less useful for imaging of AS than
for imaging of active RA [16,22-24].
Figure 1 Positron emission tomography (PET) and magnetic resonance imaging (MRI) images of a patient with high disease activity.
Coronal [18F]FDG (a) PET and (b) PET- computed tomography (PET-CT) and coronal [11C](R)PK11195 (c) PET and (d) PET-CT images of sacroiliac
joints with no tracer uptake. (e) Coronal/oblique MRI (short-tau inversion recovery) of sacroiliac joints of the same patient. Bone marrow edema
is present in both sacroiliac joints (indicated by red arrows). [11C](R)PK11195, PK11195 [(R)-1-(2-chlorophenyl)-N-methyl-N(1-methyl-propyl)-3-
soquinoline carboxamide]; [18F]FDG, [18F]-fluoro-2-deoxy-D-glucose.
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There may be several explanations for the discrepancy
between [18F]FDG, [11C](R)PK11195, and [18F]fluoride
PET-CT findings. First of all, since the definite patho-
genesis of AS still has to be elucidated, it is unknown
which target site for imaging of AS is optimal [18].
Entheses are of special interest, and synovitis seems to
be less prominent in AS compared with RA [20]. In
addition, syndesmophyte formation and ankylosis, hall-
marks of AS, reflect local osteoblastic activity. Our PET-
CT findings suggest that bone formation (for example,
osteoblastic activity) may be a more prominent feature
of AS activity than inflammation. The present PET-CT
results with the different tracers, therefore, reveal inter-
esting data that may provide insights into the pathogen-
esis of AS.
Secondly, tracer biodistribution may be related to
varying tracer characteristics. Uptake mechanisms are
different for each tracer. In (red) bone marrow, [11C](R)
PK11195 PET scans showed a diffuse increased uptake
pattern which could possibly overwhelm potential small
focal activity spots in or around bone. [18F]FDG is prob-
ably a useful marker for synovitis [16,22,23] and osteo-
myelitis [31,32] but may be less suited for detection of
(non- or low-inflammatory) bone formation in AS
[33-37]. In general, [18F]FDG seems to be more useful
for detection of osteolytic than for osteoblastic lesions
[38]. [18F]Fluoride, on the other hand, reflects osteoblas-
tic activity because of the tracer’s uptake into hydroxya-
patite crystals, which form the mineral fluoroapatite
within bone, especially at sites of bone formation
[27,28,39]. Our positive results with [18F]fluoride PET-
CT in both vertebral column and SI joints of patients
with AS correspond with [18F]fluoride PET-CT findings
of Strobel and colleagues [29] in SI joints of patients
with AS and osteo-articular [18F]fluoride findings of Ben
Ali and colleagues [40], indicating that [18F]fluoride is a
potential tracer for active bone sites in AS.
A third explanation for the differences in uptake of
the three tracers might be related to patient selection.
Patients were categorized in low or high disease activity
group according to the BASDAI level. BASDAI is a
patient questionnaire commonly used to assess disease
activity in AS. Congruent imaging results (no active
lesions) were found in four out of five patients with low
disease activity, corresponding to BASDAI measure-
ments. In contrast, in patients with high disease activity
(BASDAI ≥ 4), three out of seven patients with AS did
not show any active inflammation on MRI. This
Figure 2 [18F]FDG and [18F]fluoride PET-CT and MRI images of patients 1 (a-e) and 2 (f-j). Both patients underwent an extra [18F]fluoride
PET-CT scan. Coronal PET (a, c, f, h) and PET-CT (b, d, g, i) images obtained with [18F]FDG (a, b, f, g) and [18F]fluoride (c, d, h, i). Multiple hotspots
are shown; two examples are indicated by the red closed arrows (c, h). (e) Sagittal MRI image (STIR) of vertebral column and (j) coronal/oblique
MRI (STIR) of sacroiliac joints. Multiple lesions with increased signal (bone marrow edema) are shown; an example is indicated by the open
arrow. [18F]FDG, [18F]-fluoro-2-deoxy-D-glucose; MRI, magnetic resonance imaging; PET, positron emission tomography; PET-CT, positron emission
tomography-computed tomography; STIR, short-tau inversion recovery.
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corresponds to findings of others who did not find any
association between MRI and clinical data [41,42].
Therefore, high BASDAI scores with negative MRI may
be more related to secondary degenerative changes and
ankylosis rather than active inflammation. This is sup-
ported by the finding that six out of seven patients with
high disease activity showed bony structural lesions in
one or more vertebral bodies; at least 50% of these
lesions had degenerative characteristics. Indeed, nowa-
days, the BASDAI is criticized, and recent studies
express the belief that the ankylosing spondylitis disease
activity score (ASDAS) is a better selection criterion
than BASDAI [43-45]. Furthermore, NSAIDs were con-
tinued if used at inclusion. In theory, NSAID use may
have suppressed inflammatory activity; however, Gasper-
sic and colleagues [46] showed that anti-inflammatory
drugs have no influence on monitoring AS with MRI. In
our study, NSAIDs did not seem to influence [18F]
fluoride uptake in active lesions since PET-CT scans
depicted 17 hotspots in the two patients scanned with
this tracer.
PET-CT data were compared with MRI and conven-
tional radiographs as references. Focusing on the two
patients additionally scanned with [18F]fluoride PET-CT,
most MRI lesions corresponded to lesions with [18F]
fluoride uptake on the PET scan. Additionally, two
active [18F]fluoride PET-CT lesions in SI joints showed
subchondral fatty marrow infiltration on MRI. Although
the exact significance of subchondral fatty marrow infil-
tration is not yet clear, it is believed to be a late struc-
tural change due to chronic inflammation in AS [47].
On the other hand, in 11 out of 17 [18F]fluoride PET-
positive lesions, structural changes were found on con-
ventional x-rays. (Secondary) degenerative changes such
as sclerosis and facet arthrosis may result in a positive
[18F]fluoride signal. However, these lesions could also
Table 2 Comparison of PET-CT outcome with MRI and conventional radiography of subpopulation scanned with [18F]
FDG, [11C](R)PK11195, and [18F]fluoride
Patient Anatomic location X-ray PET-CTa MRI
Scoreb Level Lesion [18F]FDG [18F]Fluoride T1+Gd STIR
Cervical 0 2 p FA - - -
3 p FA
7 p 7 p 7 p
8 a SC 8a 8 a 8 a 8 a
9 a SC 9 a 9 a 9 a
1 Spine Thoracic 0 10 a SC 10 a 10 a 10 a
11 a SC 11 a 11 a 11 a
12 a SC
Lumbar 0 4 p FA - 4 p - -
5 p FA 5 p
Sacroiliac joints 2 2 R L SC SC
Cervical 0 - - - - 6 a 6 a
7 a 7 a
1 p 1 p 1 p
6 p
8 p
Thoracic 0 9 a/p SQ 9 p
Spine 10 a/p SQ 10a 10 p
2 11 a/p SQ 11a 11 p
12 a/p SQ
- 2 a 2 a
3 a
Lumbar 2 4 a SQ
5 a
Sacroiliac joints 4 3 R L Ank SC - - R L Ank
sfmi
Ank
sfmi
Ank
sfmi
Ank
sfmi
Levels on positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) scans are hotspots with increased signal. a[11C]
(R)PK11195 is not presented, because all scans were negative. bX-ray according to modified Stoke Ankylosing Spondylitis Spinal Score (m-SASSS) (0 to 72). a,
anterior; Ank, ankylosis; [11C](R)PK11195, PK11195 [(R)-1-(2-chlorophenyl)-N-methyl-N(1-methyl-propyl)-3-soquinoline carboxamide]; FA, facet arthrosis; L, left; p,
posterior; R, right; SC, sclerosis; sfmi, subchondral fatty marrow infiltration; SQ, squaring; STIR, short-tau inversion recovery; T1+Gd, gadolinium contrast uptake on
T1 images.
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reflect chronic AS disease activity (the mean symptom
duration of patients 11 and 12 was 22 years). Indeed,
degenerative changes as well as other structural changes
such as squaring and syndesmophyte formation can
coexist with chronic inflammation [48]. Finally, the
observed [18F]fluoride hotspots in the sternum and
shoulder seemed to correlate with clinical symptoms of
patients, again underlining the potential of [18F]fluoride
PET-CT to visualize active sites in AS.
Conclusions
Despite the limited number of patients investigated in
this study, our PET-CT results suggest that AS activity
was reflected by bone formation and not by inflamma-
tion, and this finding throws an interesting light on the
pathogenesis of the disease. In addition, [18F]fluoride
PET-CT seems to be a promising imaging technique for
detecting active lesions in the spine and SI joints of
patients with AS, but the definite value of [18F]fluoride
PET-CT as a diagnostic tool for assessment of AS activ-
ity needs to be further explored in future studies with
larger cohort(s) of patients with AS.
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